Screening and Assessment Archives

Course and Resource Listing

Medication and Behavioral Treatment of Substance Use Disorders

Format: Module

Introduces evidence-based clinical practices of pharmacotherapy and behavioral treatments for substance use disorders. Off label medications and psychosocial support programs are also discussed.

Target Audience(s):
Interprofessional Teams, Nurses, PAs, Pharmacists, Physicians, Social Workers

Topic(s):
SUD101, 12 Step Programs, Acamprosate, Acute Pain, Agonist / Partial Agonist Withdrawal, Alcohol, Alcohol, Alcohol, Amphetamines, Antagonist ...

Presenter(s):
Brian Fuehrlein, MD, PhD

Credit Available:
CE Credit(s): Yes
Designations: AMA PRA Category 1 Credit™, Nursing Contact Hour(s), Pharmacy CE Credit, AAPA Category 1 CME Credit, Social Work CE Credit, and IPCE Credit

Organizer(s):
American Academy of Addiction Psychiatry

Buprenorphine Prescribing for Pediatric Patients in the Emergency Department

Format: Podcast

This podcast will be published on the SAEM website and in promotional materials, such as our weekly newsletter, to inform learners of the activity’s contents and goals.

Target Audience(s):
Pharmacists, PAs, Physicians, Students and Educators

Topic(s):
Co-Occurring SUD / Medical Disorders, Adolescent / At Risk Youth, Adolescent Behavioral Therapies, Adolescents, Adverse Childhood Experiences, Buprenorphine, Buprenorphine, Developmental Risks, Emergency Medicine, Emergency Setting ...

Presenter(s):
Madeline Renny, MD; Sarah Bagley, MD, MSc; and Jennifer Love, MD,

Credit Available:
CE Credit(s): No
Certificate: No

Organizer(s):
Society for Academic Emergency Medicine (SAEM)

What Now: Relevance of Xylazine in the Age of Opioid Use Disorder – Guidance for OUD Treatment Providers

Format: Webinar

As the opioid use crisis continues to progress, communities across the country are now being faced with additional dangers such as the misuse of Xylazine, a powerful sedative commonly used for animals in the drug supply. Recent studies indicate these potent substances when used with opioids increase overdose risk and complicates treatment and long-term healthcare. Join us today as we discuss the history and context of Xylazine and opioid use as well as options for treatment and care.

Target Audience(s):
Administrative Staff, Counselors, Interprofessional Teams, Nurses, PAs, Pharmacists, Physicians, Psychologists, Social Workers

Topic(s):
Basic Science, Agonist / Partial Agonist Withdrawal, Antagonist, Buprenorphine, Buprenorphine, Co-Occurring SUD / Medical Disorders, Discrimination, Diversity, Emergency Medicine, Emergency Setting ...

Presenter(s):
Daniel Rosa, MD, FASAM

Credit Available:
CE Credit(s): Yes
Designations: AMA PRA Category 1 Credit™, Nursing Contact Hours, AAPA Category 1 CME, Social Work CE Credit, Pharmacy CE Credit, Interprofessional Continuing Education (IPCE) Credit

Organizer(s):
National Council for Mental Wellbeing

Interdisciplinary Care in Opioid Treatment: The Role of Counselors in Opioid Treatment — Guiding the Path to Recovery

Format: Webinar

In the fourth part of this series, we will delve into the indispensable role of counselors within the interdisciplinary care framework for opioid use disorder. Discover the techniques and strategies they use to provide emotional and psychological support, helping individuals navigate the complex path to recovery.

Target Audience(s):
Counselors, Interprofessional Teams, Psychologists, Social Workers, Students and Educators

Topic(s):
Treatment, Antagonist, Chronic Disease Model, Full Agonists, Medications, Mutual Supports, Opioids, Opioids, Opioids, Partial Agonists ...

Presenter(s):
Chrissie S. Martin, MA, LMFT, LAC-S, CS

Credit Available:
CE Credit(s): Yes
Designations: Social Work CE Credit
Certificate: Certificate of Completion

Organizer(s):
NAADAC, the Association for Addiction Professionals

Stimulant Use Disorder Pocket Guide for Patients

Format: Clinical Tool

Developed by AAAP and ASAM, this guideline focuses on the identification, diagnosis, treatment, and promotion of recovery for patients with stimulant use disorder, stimulant intoxication, and stimulant withdrawal.